BOOK
Imaging in Oncology, An Issue of Surgical Oncology Clinics of North America, E-Book
(2014)
Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, devoted to Imaging in Oncology, is edited by Dr. Vijay Khatri. Articles in this issue include: Imaging of Central Nervous Tumors; Role of Imaging in Head and Neck Malignancies; Imaging of Thoracic Cavity Tumor; Diagnostic Imaging of Hepatobiliary Malignancies; Recent Advances in Genito-Urinary Tract Tumors; Current Status of Imaging for Adrenal Glands; Radiology of Soft Tissue Tumors; Image-Guided Interventions in Oncology; Imaging of Pancreatic Neoplasms; Imaging of Primary Malignant Tumors of Peritoneal and Retroperitoneal Origin; Breast Tumor Imaging; and Application of Intraoperative Imaging in Oncology.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Imaging in Oncology\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | vii | ||
| Surgical Oncology Clinics Of North America\r | x | ||
| Foreword\r | xi | ||
| Preface\r | xiii | ||
| Erratum | xv | ||
| Imaging of Brain Tumors | 629 | ||
| Key points | 629 | ||
| Conventional imaging techniques in brain tumors | 629 | ||
| Advanced MRI techniques in brain tumors | 630 | ||
| Diffusion-Weighted Imaging and Diffusion Tensor Imaging | 630 | ||
| Perfusion-Weighted Imaging | 631 | ||
| Spectroscopy | 635 | ||
| fMRI | 637 | ||
| Presurgical localization of eloquent cortical areas | 637 | ||
| Lateralization (dominant hemisphere) | 637 | ||
| Functional neuronavigation | 638 | ||
| Brain tumors | 640 | ||
| Cerebral Gliomas | 640 | ||
| Pilocytic astrocytoma | 640 | ||
| Terminology | 640 | ||
| Epidemiology | 640 | ||
| Location | 640 | ||
| Pathology | 640 | ||
| Clinical presentation | 640 | ||
| Imaging | 640 | ||
| Differential diagnosis | 641 | ||
| Therapy and prognosis | 642 | ||
| Low-grade infiltrative astrocytoma | 642 | ||
| Terminology | 642 | ||
| Epidemiology | 642 | ||
| Value of Imaging in Head and Neck Tumors | 685 | ||
| Key points | 685 | ||
| Introduction: nature of the problem | 685 | ||
| Preimaging planning | 686 | ||
| Relevant Anatomy | 686 | ||
| Sinonasal | 686 | ||
| Salivary gland | 687 | ||
| Nasopharynx | 687 | ||
| Oral cavity and oropharynx | 689 | ||
| Larynx and hypopharynx | 689 | ||
| Thyroid | 689 | ||
| Rationale/issues for modality selection | 690 | ||
| Interpretation/assessment of clinical images | 690 | ||
| Sinonasal | 691 | ||
| Salivary Gland Tumors | 694 | ||
| Nasopharynx | 695 | ||
| Oral Cavity and Oropharynx | 697 | ||
| Larynx and Hypopharynx | 699 | ||
| Thyroid | 700 | ||
| Posttherapy assessment | 702 | ||
| Suprahyoid Malignancy | 702 | ||
| Infrahyoid Malignancy | 703 | ||
| Summary | 703 | ||
| References | 704 | ||
| Imaging of Thoracic Cavity Tumors | 709 | ||
| Key points | 709 | ||
| Introduction | 709 | ||
| Lung cancer | 710 | ||
| Diagnosis | 710 | ||
| Histologic subtypes | 710 | ||
| Screening | 712 | ||
| Evaluation of pulmonary nodules | 713 | ||
| MRI in lung cancer diagnosis | 714 | ||
| Tissue diagnosis | 714 | ||
| Staging | 714 | ||
| Treatment | 715 | ||
| Follow-up | 717 | ||
| Other Primary Lung Tumors | 718 | ||
| Mediastinal tumors | 718 | ||
| Relevant Anatomy | 718 | ||
| Diagnosis | 719 | ||
| Pretreatment Evaluation | 719 | ||
| Thymic Tumors | 719 | ||
| Lymphoma | 720 | ||
| Germ Cell Tumors | 720 | ||
| Mediastinal Cysts | 722 | ||
| Neurogenic Tumors | 722 | ||
| Pleural tumors | 722 | ||
| Relevant Anatomy | 722 | ||
| Diagnosis | 722 | ||
| Pretreatment Evaluation | 724 | ||
| Malignant Pleural Mesothelioma | 725 | ||
| Fibrous Pleural Tumor | 725 | ||
| Summary | 727 | ||
| References | 727 | ||
| Emerging Modalities in Breast Cancer Imaging | 735 | ||
| Key points | 735 | ||
| Introduction | 735 | ||
| Ultrasonography refinements | 736 | ||
| DBT | 737 | ||
| Dedicated bCT | 741 | ||
| Nuclear medicine and breast imaging | 745 | ||
| CEDM | 745 | ||
| Summary | 746 | ||
| References | 746 | ||
| Imaging of Pancreatic Neoplasms | 751 | ||
| Key points | 751 | ||
| Introduction | 751 | ||
| Anatomy | 752 | ||
| Technique | 754 | ||
| Ultrasound | 754 | ||
| Computed Tomography | 754 | ||
| Magnetic Resonance Imaging | 755 | ||
| Octreotide or Somatostatin Receptor Scintigraphy (SRS) | 755 | ||
| Positron Emission Tomography–CT | 755 | ||
| Gallium 68–Labeled PET Imaging | 756 | ||
| Endoscopic US | 756 | ||
| Pancreatic neoplasms | 756 | ||
| PDAC | 756 | ||
| Epidemiology | 756 | ||
| Risk factors | 756 | ||
| Hereditary and familial risk factors | 756 | ||
| Hereditary pancreatitis | 756 | ||
| BRCA mutations | 756 | ||
| Peutz-Jeghers syndrome | 756 | ||
| Familial atypical multiple mole melanoma syndrome | 757 | ||
| Hereditary nonpolyposis colon cancer or Lynch syndrome | 757 | ||
| Familial pancreatic cancer | 757 | ||
| Imaging appearance | 757 | ||
| US | 757 | ||
| MDCT | 757 | ||
| MRI | 759 | ||
| PET-CT | 759 | ||
| Staging of PDAC | 759 | ||
| PanNETs | 763 | ||
| Epidemiology | 763 | ||
| Risk Factors | 763 | ||
| MEN I | 763 | ||
| vHL syndrome | 764 | ||
| Tuberous sclerosis | 764 | ||
| Imaging | 764 | ||
| Insulinoma | 764 | ||
| US | 765 | ||
| MDCT | 765 | ||
| MRI | 766 | ||
| Nuclear medicine imaging | 766 | ||
| Gastrinoma | 767 | ||
| US | 767 | ||
| MDCT | 767 | ||
| MRI | 768 | ||
| Nuclear medicine imaging | 768 | ||
| Octreotide scan | 768 | ||
| 68-Ga-labeled PET | 768 | ||
| Nonfunctional PanNET | 768 | ||
| US | 769 | ||
| MDCT | 769 | ||
| MRI | 769 | ||
| Nuclear medicine imaging | 770 | ||
| Octreotide scan | 770 | ||
| 18F FDG PET-CT | 770 | ||
| 68Ga-labeled PET | 770 | ||
| Unusual appearance and patterns of spread PanNETs | 771 | ||
| Staging | 772 | ||
| Cystic pancreatic lesions | 772 | ||
| Epidemiology | 772 | ||
| Risk Factors | 773 | ||
| Imaging | 773 | ||
| Pseudocysts | 773 | ||
| US | 774 | ||
| MDCT | 774 | ||
| MRI | 774 | ||
| EUS FNA | 774 | ||
| SPEN | 774 | ||
| US | 775 | ||
| MDCT | 775 | ||
| MRI | 775 | ||
| EUS FNA | 775 | ||
| MCNs | 776 | ||
| US | 776 | ||
| MDCT | 776 | ||
| MRI | 776 | ||
| EUS FNA | 776 | ||
| SCAs | 777 | ||
| US | 777 | ||
| MDCT | 777 | ||
| MRI | 777 | ||
| EUS FNA | 778 | ||
| IPMNs | 778 | ||
| US | 779 | ||
| MDCT | 779 | ||
| MRI | 780 | ||
| EUS FNA | 780 | ||
| International consensus criteria | 780 | ||
| Summary | 781 | ||
| References | 782 | ||
| Diagnostic Imaging of Hepatic Lesions in Adults | 789 | ||
| Key points | 789 | ||
| Introduction | 789 | ||
| Magnetic resonance imaging | 790 | ||
| Multidetector computed tomography | 791 | ||
| Ultrasonography | 794 | ||
| Nuclear medicine | 795 | ||
| Malignant liver masses | 795 | ||
| Hepatocellular Carcinoma | 795 | ||
| Imaging features | 795 | ||
| Liver imaging reporting and data system | 798 | ||
| Fibrolamellar HCC | 798 | ||
| Imaging features | 798 | ||
| Intrahepatic Cholangiocarcinoma | 799 | ||
| Imaging features | 800 | ||
| Mass-like | 800 | ||
| Periductal-infiltrating type | 801 | ||
| Intraductal-growing type | 801 | ||
| Epithelioid Hemangioendothelioma | 801 | ||
| Primary Malignant Tumors of Peritoneal and Retroperitoneal Origin | 821 | ||
| Key points | 821 | ||
| Introduction | 821 | ||
| Anatomic considerations | 822 | ||
| Primary peritoneal malignancies | 823 | ||
| Papillary Serous Carcinoma | 823 | ||
| Current Status of Imaging for Adrenal Gland Tumors | 847 | ||
| Key points | 847 | ||
| Preimaging planning | 847 | ||
| Normal Adrenal Gland | 847 | ||
| Principles and Rationales for Imaging Studies | 848 | ||
| Diagnostic imaging techniques | 849 | ||
| CT | 849 | ||
| MRI | 849 | ||
| PET | 850 | ||
| Interpretation and assessment of clinical images | 850 | ||
| Adenoma | 850 | ||
| Myelolipoma | 852 | ||
| Cyst and Pseudocyst | 852 | ||
| Adrenal Hemorrhage | 852 | ||
| Pheochromocytoma | 853 | ||
| Adrenocortical Carcinoma | 855 | ||
| Metastasis | 855 | ||
| Options/pathways for surgical intervention | 856 | ||
| Hyperfunctioning Tumor | 856 | ||
| Incidental Adrenal Mass | 858 | ||
| Summary | 859 | ||
| References | 859 | ||
| Recent Advances in Imaging Cancer of the Kidney and Urinary Tract | 863 | ||
| Key points | 863 | ||
| Cancer of the kidney | 863 | ||
| Epidemiology of Renal Cancer | 863 | ||
| New and Expanded Roles for Radiologic Imaging of Renal Cancer | 864 | ||
| Radiologic Imaging for Detection, Characterization, and Staging of RCC | 864 | ||
| US | 865 | ||
| CT | 866 | ||
| Limitations of CT | 870 | ||
| MRI | 870 | ||
| Limitations of MRI | 871 | ||
| Positron emission tomography | 872 | ||
| Imaging of Histologic Subtypes of RCC | 872 | ||
| New Techniques of Radiologic Imaging for Detection, Characterization, and Staging of RCC | 875 | ||
| CT | 875 | ||
| Dual-energy CT | 875 | ||
| CT scanning with lower radiation dose | 877 | ||
| MRI | 877 | ||
| DWI | 877 | ||
| Perfusion-weighted imaging | 883 | ||
| Immuno-PET | 883 | ||
| Follow-Up After Treatment of RCC | 884 | ||
| Monitoring after local ablative or surgical treatment | 884 | ||
| Determining response after treatment of metastatic disease | 887 | ||
| Cancer of the urinary bladder | 888 | ||
| Epidemiology and Pathology of Bladder Cancer | 888 | ||
| Radiologic Imaging for Detection of Bladder Cancer | 889 | ||
| Evolving techniques for detection of bladder cancer | 891 | ||
| MRI | 891 | ||
| Radiologic Imaging for Staging of Bladder Cancer | 891 | ||
| CT | 891 | ||
| MRI | 895 | ||
| New Imaging Techniques for Staging of Bladder Cancer | 896 | ||
| Diffusion-weighted MRI | 896 | ||
| PET | 898 | ||
| Imaging Surveillance After Treatment of Bladder Cancer | 899 | ||
| Upper urinary tract urothelial cancer | 899 | ||
| Epidemiology and Patterns of Involvement of UT Urothelial Cancer | 899 | ||
| Radiologic Imaging for Detection and Staging of UT Urothelial Cancer | 900 | ||
| MDCT urography | 900 | ||
| RUP and retrograde ureteropyeloscopy | 903 | ||
| MRU | 903 | ||
| Staging of UT urothelial cancer with radiologic imaging | 903 | ||
| Surveillance of Patients Diagnosed with UT Urothelial Cancer with Radiologic Imaging | 905 | ||
| References | 905 | ||
| Radiology of Soft Tissue Tumors | 911 | ||
| Key points | 911 | ||
| Introduction | 911 | ||
| Background | 911 | ||
| Sarcomas | 912 | ||
| Role of the Radiologist | 913 | ||
| Preimaging planning | 913 | ||
| Diagnostic imaging technique | 915 | ||
| Pearls and Pitfalls | 915 | ||
| Interpretation/assessment of clinical images | 916 | ||
| Synovial Sarcoma | 916 | ||
| Fibromatosis | 916 | ||
| Myxoma | 917 | ||
| Nodular Fasciitis | 917 | ||
| Interpreting Soft Tissue Masses on Radiographs | 917 | ||
| Interpreting Soft Tissue Masses on CT | 918 | ||
| Interpreting Soft Tissue Masses on MRI | 918 | ||
| Examples of specific lesions | 920 | ||
| Lipomas and Lipomatous Lesions | 920 | ||
| Hemangiomas and Vascular Malformations | 920 | ||
| Ganglion | 921 | ||
| Peripheral Nerve Sheath Tumors | 921 | ||
| GCT-TS | 923 | ||
| Myositis Ossificans | 924 | ||
| Hematoma | 925 | ||
| Morel Lavallée Lesion | 928 | ||
| Morton Neuroma | 928 | ||
| Elastofibroma | 928 | ||
| Biopsy | 929 | ||
| Technique | 931 | ||
| Pitfalls | 932 | ||
| Tips | 932 | ||
| Options/pathways for surgical intervention | 932 | ||
| Summary | 932 | ||
| References | 933 | ||
| Image-Guided Interventions in Oncology | 937 | ||
| Key points | 937 | ||
| Introduction | 937 | ||
| Clinical use of image-guided interventions | 938 | ||
| Cancer Diagnosis | 938 | ||
| Portal Vein Embolization | 938 | ||
| Cancer Treatment | 940 | ||
| Transarterial hepatic treatments | 940 | ||
| Nonhepatic transarterial treatment | 942 | ||
| Percutaneous ablation therapy | 944 | ||
| Management of Cancer Complications | 945 | ||
| Biliary drainage | 945 | ||
| Urologic interventions | 946 | ||
| Pain management | 948 | ||
| Treatment of vascular complications | 948 | ||
| Summary | 949 | ||
| References | 949 | ||
| Index | 957 |